{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:12:53Z","timestamp":1793643173053,"version":"4.5.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.beem.2022.101684","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T19:11:26Z","timestamp":1657998686000},"page":"101684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Second line treatment of acromegaly: Pasireotide or Pegvisomant?"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9241-2392","authenticated-orcid":false,"given":"Sabrina","family":"Chiloiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Giampietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rald","family":"Raverot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura De","family":"Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2022.101684_bib1","series-title":"The pituitary","first-page":"433","article-title":"Acromegaly","author":"Melmed","year":"2010"},{"issue":"2","key":"10.1016\/j.beem.2022.101684_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"A\u00a0meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly","volume":"159","author":"Holdaway","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2022.101684_bib3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The future of somatostatin receptor ligands in acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2022.101684_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4158\/EP14430.RA","article-title":"Acromegaly: assessing the disorder and navigating therapeutic options for treatment","volume":"20","author":"Melmed","year":"2014","journal-title":"Endocr Pract"},{"key":"10.1016\/j.beem.2022.101684_bib5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1530\/EJE-14-0844","article-title":"The participants of the German Acromegaly Register. Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey","volume":"172","author":"Sch\u00f6fl","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2022.101684_bib6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1210\/jc.2014-2468","article-title":"A\u00a0structural and functional acromegaly classification","volume":"100","author":"Cuevas-Ramos","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2022.101684_bib7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1210\/er.2010-0002","article-title":"Resistance to somatostatin analogs in acromegaly","volume":"32","author":"Colao","year":"2011","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2022.101684_bib8","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/BF03347378","article-title":"Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3","volume":"29","author":"Casarini","year":"2006","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2022.101684_bib9","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1210\/jc.2006-2084","article-title":"Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient","volume":"92","author":"Resmini","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.beem.2022.101684_bib10","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1210\/jc.2008-0126","article-title":"Prognostic significance of the ki-67 labeling index in growth hormone-secreting pituitary adenomas","volume":"93","author":"Fusco","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101684_bib11","first-page":"32","article-title":"Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes","volume":"21","author":"Bianchi","year":"2013","journal-title":"J\u00a0Exp Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.beem.2022.101684_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-13-0349","article-title":"Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern","volume":"169","author":"Kasuki","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"76","key":"10.1016\/j.beem.2022.101684_bib13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","article-title":"Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly","author":"Fougner","year":"2012","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101684_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.mce.2015.09.016","article-title":"Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors","volume":"417","author":"Kiseljak-Vassiliades","year":"2015","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2022.101684_bib15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2022.101684_bib16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1677\/JME-08-0162","article-title":"The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology","volume":"42","author":"Ferone","year":"2009","journal-title":"J\u00a0Mol Endocrinol"},{"issue":"22","key":"10.1016\/j.beem.2022.101684_bib17","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/jcmm.13440","article-title":"Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly","author":"Venegas-Moreno","year":"2018","journal-title":"Cell. Mol. Med."},{"issue":"2","key":"10.1016\/j.beem.2022.101684_bib18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101684_bib19","series-title":"WHO Classification of tumours of endocrine organs","author":"Lloyd","year":"2017"},{"key":"10.1016\/j.beem.2022.101684_bib20","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1177\/0091270011408727","article-title":"Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers","volume":"52","author":"Petersenn","year":"2012","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.beem.2022.101684_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.beem.2022.101684_bib22","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3390\/ijms21051682","article-title":"Somatostatin analogs in clinical practice: a review","volume":"21","author":"Gomes-Porras","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.beem.2022.101684_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tem.2009.12.003","article-title":"Pituitary somatostatin receptor signaling","volume":"21","author":"Ben Shlomo","year":"2010","journal-title":"Trends Endocrinol Metabol"},{"issue":"4","key":"10.1016\/j.beem.2022.101684_bib24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/jpm9040048","article-title":"Role of receptor profiling for personalized therapy in a patient with a growth hormone-secreting macroadenoma resistant to first-generation somatostatin analogues","volume":"9","author":"Alexandraki","year":"2019","journal-title":"J\u00a0Personalized Med"},{"key":"10.1016\/j.beem.2022.101684_bib25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1530\/EJE-08-0822","article-title":"Pituitary-independent effect of octreotide on IGF1 generation","volume":"160","author":"Pokrajac","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101684_bib26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1172\/JCI19933","article-title":"Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis","volume":"114","author":"Murray","year":"2004","journal-title":"J\u00a0Clin Investig"},{"issue":"3","key":"10.1016\/j.beem.2022.101684_bib27","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"C2305 Study group. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101684_bib28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2022.101684_bib29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-18-0353","article-title":"Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study","volume":"179","author":"Muhammad","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2022.101684_bib30","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s12020-021-02782-2","article-title":"Long-term safety and efficacy of long-acting pasireotide in acromegaly","volume":"74","author":"Akirov","year":"2021","journal-title":"Endocrine"},{"issue":"10","key":"10.1016\/j.beem.2022.101684_bib31","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1530\/EC-19-0332","article-title":"Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study","volume":"8","author":"Lasolle","year":"2019","journal-title":"Endocr Connect"},{"key":"10.1016\/j.beem.2022.101684_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.633944","article-title":"The effect of 6 Months' treatment with pasireotide LAR on glucose metabolism in patients with resistant acromegaly in real-world clinical settings","author":"Witek","year":"2021","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2022.101684_bib33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-20-0767","article-title":"Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response","volume":"184","author":"Chiloiro","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2022.101684_bib34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11102-021-01185-w","article-title":"Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation","volume":"25","author":"Stelmachowska-Bana\u015b","year":"2022","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.beem.2022.101684_bib35","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12020-018-1690-5","article-title":"Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study","volume":"62","author":"Shimon","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2022.101684_bib36","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1210\/jc.2017-00135","article-title":"In\u00a0vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas","volume":"102","author":"Gatto","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.beem.2022.101684_bib37","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3390\/cancers13081816","article-title":"Octreotide and pasireotide combination treatment in somatotroph tumor cells: predominant role of SST2 in mediating ligand effects","volume":"13","author":"Amar\u00f9","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.beem.2022.101684_bib38","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1210\/jc.2018-01524","article-title":"Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression","volume":"104","author":"Muhammad","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101684_bib39","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/modpathol.3800954","article-title":"Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy","volume":"20","author":"Volante","year":"2007","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.beem.2022.101684_bib40","doi-asserted-by":"crossref","first-page":"E1730","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide","volume":"98","author":"Casar-Borota","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101684_bib41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejphar.2010.07.005","article-title":"Absence of somatostatin SST2 receptor internalization in\u00a0vivo after intravenous SOM230 application in the AR42J animal tumor model","volume":"644","author":"Waser","year":"2010","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10.1016\/j.beem.2022.101684_bib42","doi-asserted-by":"crossref","first-page":"648411","DOI":"10.3389\/fendo.2021.648411","article-title":"Pasireotide in the personalized treatment of acromegaly","volume":"16","author":"Puig-Domingo","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2022.101684_bib43","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/EC-19-0004","article-title":"AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients","volume":"8","author":"Daly","year":"2019","journal-title":"Endocr Connect"},{"issue":"3","key":"10.1016\/j.beem.2022.101684_bib44","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1530\/JOE-17-0254","article-title":"AIP and the somatostatin system in pituitary tumours","volume":"235","author":"Ibanez-Costa","year":"2017","journal-title":"J\u00a0Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2022.101684_bib45","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"issue":"2","key":"10.1016\/j.beem.2022.101684_bib46","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/EJE-19-0762","article-title":"Pasireotide for acromegaly: long-term outcomes from an extension to the phase III PAOLA study","volume":"182","author":"Colao","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2022.101684_bib47","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12020-021-02711-3","article-title":"Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant","volume":"73","author":"Chiloiro","year":"2021","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2022.101684_bib48","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1210\/jc.2011-2508","article-title":"Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY","volume":"97","author":"van der Lely","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101684_bib49","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fendo.2018.00358","article-title":"Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment","volume":"9","author":"Ferra\u00f9","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2022.101684_bib50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fendo.2020.00028","article-title":"Cardiometabolic risk in acromegaly: a review with a focus on pasireotide","volume":"11","author":"Puglisi","year":"2020","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2022.101684_bib51","doi-asserted-by":"crossref","first-page":"dgz054","DOI":"10.1210\/clinem\/dgz054","article-title":"Effects of pegvisomant and pasireotide lar on vertebral fractures in acromegaly resistant to first-generation SRL","volume":"105","author":"Chiloiro","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101684_bib52","first-page":"47","article-title":"Profile of pegvisomant in the management of acromegaly: an evidence based review of its place in therapy","volume":"5","author":"Bernabeu","year":"2015","journal-title":"Res Rep Endocr Disord"},{"issue":"15","key":"10.1016\/j.beem.2022.101684_bib53","doi-asserted-by":"crossref","first-page":"9858","DOI":"10.1073\/pnas.152294299","article-title":"Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis","volume":"99","author":"Gent","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.beem.2022.101684_bib54","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nsmb977","article-title":"Model for growth hormone receptor activation based on subunit rotation within a receptor dimer","volume":"12","author":"Brown","year":"2005","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"10.1016\/j.beem.2022.101684_bib55","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ando.2015.10.003","article-title":"Pegvisomant treatment in patients with acromegaly in clinical practice: the French ACROSTUDY","volume":"76","author":"Chanson","year":"2015","journal-title":"Ann Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2022.101684_bib56","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12020-014-0393-9","article-title":"ACROSTUDY: the Italian experience","volume":"48","author":"Grottoli","year":"2015","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.beem.2022.101684_bib57","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1530\/EJE-17-0996","article-title":"Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant","volume":"178","author":"Strasburger","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2022.101684_bib58","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1210\/jc.2006-1412","article-title":"Gender, body weight, disease activity, and previous radiotherapy influence the response to Pegvisomant","volume":"92","author":"Parkinson","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2022.101684_bib59","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1046\/j.1365-2265.1996.672494.x","article-title":"Growth hormone-binding protein related immunoreactivity is regulated by the degree of insulinopenia in diabetes mellitus","volume":"44","author":"Kratzsch","year":"1996","journal-title":"Clin Endocrinol"},{"issue":"12","key":"10.1016\/j.beem.2022.101684_bib60","first-page":"4712","article-title":"Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation","volume":"85","author":"Leung","year":"2000","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"34","key":"10.1016\/j.beem.2022.101684_bib61","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/BF03346731","article-title":"The exon 3-deleted growth hormone receptor: molecular and functional characterization and impact on GH\/IGF-I axis in physiological and pathological conditions","author":"Filopanti","year":"2011","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"86","key":"10.1016\/j.beem.2022.101684_bib62","doi-asserted-by":"crossref","first-page":"8083","DOI":"10.1073\/pnas.86.20.8083","article-title":"Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism","author":"Godowski","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.beem.2022.101684_bib63","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12020-017-1391-5","article-title":"Prevalence of morphometric vertebral fractures in \"difficult\" patients with acromegaly with different biochemical outcomes after multimodal treatment","volume":"59","author":"Chiloiro","year":"2018","journal-title":"Endocrine"},{"issue":"105","key":"10.1016\/j.beem.2022.101684_bib64","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000448844","article-title":"The effect of the exon-3-deleted growth hormone receptor on pegvisomant-treated acromegaly: a systematic review and meta-analysis","author":"Franck","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.beem.2022.101684_bib65","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s11102-008-0157-8","article-title":"Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly","volume":"12","author":"Bianchi","year":"2009","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.beem.2022.101684_bib66","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000448429","article-title":"Somatostatin receptor expression in GH-secreting pituitary adenomas treated with long-acting somatostatin analogues in combination with pegvisomant","volume":"105","author":"Franck","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2022.101684_bib67","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.beem.2022.101684_bib68","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/nrendo.2009.175","article-title":"Somatostatin analog and pegvisomant combination therapy for acromegaly","volume":"5","author":"Neggers","year":"2009","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2022.101684_bib69","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1210\/jc.2006-2276","article-title":"The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly","volume":"92","author":"Lindberg-Larsen","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.beem.2022.101684_bib70","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40618-014-0146-x","article-title":"Use of pegvisomant in acromegaly. An Italian Society of Endocrinology guideline","volume":"37","author":"Giustina","year":"2014","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"7","key":"10.1016\/j.beem.2022.101684_bib71","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1210\/jc.2008-2086","article-title":"Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly","volume":"94","author":"Higham","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.beem.2022.101684_bib72","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2018-02281","article-title":"Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies","volume":"104","author":"Feola","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2022.101684_bib73","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s11102-018-0873-7","article-title":"Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly","volume":"21","author":"Chiloiro","year":"2018","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.beem.2022.101684_bib74","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2265.2002.01624.x","article-title":"Effects of a growth hormone receptor antagonist on bone markers in acromegaly","volume":"57","author":"Fairfield","year":"2002","journal-title":"Clin Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2022.101684_bib75","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1210\/jc.2019-00825","article-title":"Pasireotide and pegvisomant combination treatment in acromegaly resistant to second-line therapies: a longitudinal study","volume":"104","author":"Chiloiro","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"16","key":"10.1016\/j.beem.2022.101684_bib76","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"9295","key":"10.1016\/j.beem.2022.101684_bib77","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long- term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"van der Lely","year":"2001","journal-title":"Lancet"},{"issue":"9471","key":"10.1016\/j.beem.2022.101684_bib78","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(05)63011-5","article-title":"Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly","volume":"365","author":"Feenstra","year":"2005","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.beem.2022.101684_bib79","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1210\/jc.2005-0531","article-title":"Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist","volume":"90","author":"J\u00f8rgensen","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"12","key":"10.1016\/j.beem.2022.101684_bib80","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1210\/jc.2007-1234","article-title":"Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly","volume":"92","author":"Neggers","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"5","key":"10.1016\/j.beem.2022.101684_bib81","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","article-title":"Expert group on pituitary tumors. Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a pituitary society statement","volume":"20","author":"Casanueva","year":"2017","journal-title":"Pituitary"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:58:59Z","timestamp":1761497939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X22000719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1521690X22000719"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2022.101684","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second line treatment of acromegaly: Pasireotide or Pegvisomant?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2022.101684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101684"}}